# A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia

Study · id `cardio:ct-nct02057302` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02057302](<https://clinicaltrials.gov/study/NCT02057302>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02057302

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2400 participants.

## Technical summary

Registry record NCT02057302. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2400 participants (enrolled count; ClinicalTrials.gov record NCT02057302, source copy `cardio:ctgov-nct02057302-2014-02-07`, retrieved 2026-10-31)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT02057302, source copy `cardio:ctgov-nct02057302-2014-02-07`, retrieved 2026-10-31)
- Primary completion: 2012-12 (actual) (ClinicalTrials.gov record NCT02057302, source copy `cardio:ctgov-nct02057302-2014-02-07`, retrieved 2026-10-31)
- Completion: Not reported
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02057302-2014-02-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia
- Condition: Dyslipidemia
- Intervention (Drug): Xuezhikang capsule
- Lead sponsor: China Academy of Chinese Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: China Academy of Chinese Medical Sciences (`cardio:org-china-academy-of-chinese-medical-sciences`)

## Provenance

Content hash: 7d700af19f7f3894c5686805f317d8c83c537ad6bf9402c4b18e378bed0ea9be
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
